ADRM1 Antibody
Description
Introduction to ADRM1 Antibody
ADRM1 Antibody refers to immunological reagents designed to detect ADRM1 (Adhesion-Regulating Molecule 1), a ubiquitin receptor subunit of the 19S regulatory particle in the proteasome complex. This protein facilitates substrate recognition and processing within the proteasome, playing critical roles in protein degradation and cellular homeostasis . ADRM1 antibodies are essential tools for studying its expression, localization, and functional interactions in both physiological and pathological contexts.
Applications and Uses of ADRM1 Antibody
ADRM1 antibodies are validated for diverse experimental techniques, including:
Example Antibodies and Their Specificities:
-
Abcam ab157185 (EPR11449(B)): Human-specific; validated via knockout controls in WB .
-
Cell Signaling D9Z1U: Cross-reacts with human, mouse, rat, and monkey; optimized for IP .
-
Proteintech 11468-1-AP: Polyclonal antibody with broad reactivity (human, mouse, rat); used in IHC and IF .
Role in Cancer Biology
ADRM1 overexpression is associated with poor prognosis in multiple cancers:
-
Bladder Cancer (BC): High ADRM1 expression correlates with immune checkpoint markers (PD-L1, PD-1), elevated tumor mutational burden (TMB), and increased CD8+ T-cell infiltration, suggesting potential for immunotherapy .
-
Intrahepatic Cholangiocarcinoma (ICC): ADRM1 knockdown or inhibition (e.g., RA190) suppresses tumor growth in vitro and in vivo, with RA190 disrupting proteasome function via cysteine 88 binding .
-
Ovarian Cancer: ADRM1 inhibitors reverse immunosuppression mediated by myeloid-derived suppressor cells, enhancing anti-tumor immunity .
Therapeutic and Diagnostic Implications
-
Immunotherapy Prediction: High ADRM1 expression in BC predicts sensitivity to anti-PD-L1 agents (e.g., atezolizumab) due to enriched immune checkpoints and TMB .
-
Chemotherapy Response: Low ADRM1 expression in BC correlates with sensitivity to cisplatin, docetaxel, and methotrexate, guiding personalized treatment .
-
Stemness and Mutation Burden: ADRM1 expression positively correlates with mRNA stemness index (mRNAsi) and TMB, influencing treatment resistance and metastasis .
Product Specs
Product Science Overview
ADRM1 is a receptor for ubiquitin, a small regulatory protein that tags other proteins for degradation. By binding to ubiquitinated proteins, ADRM1 facilitates their recognition and processing by the proteasome. This process is vital for the regulation of protein turnover, which in turn affects numerous cellular functions such as cell cycle progression, apoptosis, and DNA repair .
Recent studies have highlighted the significance of ADRM1 in cancer development and progression. Elevated levels of ADRM1 have been observed in various types of cancers, including bladder cancer. In bladder cancer, high ADRM1 expression is associated with poor prognosis and increased tumor aggressiveness. ADRM1’s role in cancer is linked to its involvement in regulating immune-related pathways and its interaction with immune checkpoints such as CD274 (PD-L1), PDCD1 (PD-1), and PDCD1LG2 (PD-L2) .
Mouse anti-human ADRM1 antibodies are monoclonal antibodies developed to specifically target the human ADRM1 protein. These antibodies are used in research to study the expression and function of ADRM1 in various biological contexts. They are particularly valuable in immunohistochemistry (IHC) and other immunoassays to detect ADRM1 in tissue samples and cell lines .
The use of mouse anti-human ADRM1 antibodies has facilitated numerous studies aimed at understanding the role of ADRM1 in health and disease. For instance, these antibodies have been employed to investigate the expression patterns of ADRM1 in cancer tissues, providing insights into its potential as a biomarker for cancer diagnosis and prognosis. Additionally, research utilizing these antibodies has contributed to the development of targeted therapies aimed at modulating ADRM1 activity to improve cancer treatment outcomes .
